Last update :
16/06/2024
Anticancer drug   Durvalumab  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Imfinzi Canada, France, Germany, Great Britain, Switzerland, United States of America
Stability in solutions   Injection   Stability in solutions : Durvalumab     
Container Solvent Concentration Temperature Storage Duration of stability References
Partially used vials None 50 mg/ml 2-8°C Protect from light
28 Day
4767
Level of evidence D

Partially used vials None 50 mg/ml 20-25°C Protect from light
28 Day
4767
Level of evidence D

Partially used vials None 50 mg/ml 20-25°C Light
14 Day
4772
Level of evidence A+

Partially used vials None 50 mg/ml 4°C Protect from light
14 Day
4772
Level of evidence A+

Not specified NaCl 0,9% or Glucose 5% 1 >> 15 mg/ml 2-8°C Not specified
30 Day
4608
Manufacturer's stability data

Not specified NaCl 0,9% or Glucose 5% 1 >> 15 mg/ml 25°C Not specified
24 Hour
4608
Manufacturer's stability data


  Mentions Légales